Research programme: kidney disorder therapeutics - Goldfinch Bio
Latest Information Update: 17 Feb 2017
At a glance
- Originator Goldfinch Bios
- Developer Goldfinch Bio
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Focal segmental glomerulosclerosis; Polycystic kidney disease
Most Recent Events
- 09 Feb 2017 Early research in Focal segmental glomerulosclerosis in USA (unspecified route) (Goldfinch Bio pipeline, February 2017)
- 09 Feb 2017 Early research in Polycystic kidney disease in USA (unspecified route) (Goldfinch Bio pipeline, February 2017)